Interestingly, it was reported that there was a stratification of high and low plasma TNFSF13B in melanoma patients treated with anti-PD1/PDL1 therapy, which again hinted that TNFSF13B shared extensive heterogeneity between patients [46]. Here, TNFSF13B is linked to melanoma.